CDI-31244 + sofosbuvir + velpatasvir

CDI-31244 + sofosbuvir + velpatasvir is an investigational, oral, short-duration combination therapy for the treatment of chronic hepatitis C virus infection (HCV), specifically genotype 1. This regimen combines CDI-31244, a potent, selective, oral non-nucleoside inhibitor (NNI) of HCV NS5B RNA-dependent RNA polymerase, with sofosbuvir (a nucleotide NS5B polymerase inhibitor) and velpatasvir (an NS5A inhibitor), components of the approved fixed-dose combination Epclusa. CDI-31244 is designed to deliver high concentrations to the liver, with minimal off-target effects on human polymerases, and aims to provide effective HCV therapy with a shorter treatment duration. The combination has shown promising virologic response rates in phase 2 trials, with no significant pharmacokinetic interactions or unexpected safety signals[2][4][5].